MiMedx (MDXG) Q3 2026 Earnings Call Transcript

MiMedx reported Q3 2026 net sales of $62 million, down 45% year over year, including Surgical revenue up 9% to $40 million and Wound sales down 71% to $22 million amid Medicare reimbursement changes. Adjusted EBITDA was $2 million, a $10 million sequential improvement, while GAAP net loss was $9 million; the company lowered FY 2026 sales guidance to $250 million–$260 million. The FTC’s second request has delayed the proposed Sanara acquisition; management cited expected combined-company revenue near $400 million and more than $20 million in annualized cost synergies, contingent on closing.

Analysis

MDXG’s recovery is more a cost-reset story than a demonstrated demand recovery: Surgical volume is growing, but Wound remains exposed to reimbursement-driven price and volume pressure. The key second-order risk is that buying Sanara converts a net-cash balance sheet into a materially leveraged one before the acquired scale and synergies are proven. At SOFR + 6.25%, delay also creates carrying-cost exposure; the promised >20% margin and rapid deleveraging are management targets, not yet validated outcomes. Treat the FTC second request as a timing and financing risk, not evidence of a likely block. For SMTI, the delay extends uncertainty around transaction completion; deal terms and standalone valuation are not supplied, so direction is not actionable from this information alone.

Contrarian point: sequential EBITDA improvement can overstate underlying operating momentum when the driver is cost reduction against a sharply smaller revenue base. Conversely, Surgical volume growth and the AXIOFILL court ruling could be underappreciated, but the ruling remands the issue to FDA—it is not a final regulatory clearance. The patent settlement provides staged cash receipts, not recurring operating earnings, and outcomes in the other cases remain uncertain.

Near term, FTC progress, the final Medicare fee schedule, and 510(k) decisions are the catalysts. Over 6–18 months, the thesis depends on sustaining Surgical growth, stabilizing Wound pricing/volume, and realizing acquisition synergies. Falsifiers include further Wound deterioration, Surgical growth falling below guidance, delayed or adverse FTC action, or combined leverage failing to decline as projected.

Key Decisions for Investors

• Do not underwrite MDXG’s acquisition case on management’s synergy or margin targets alone. Wait for FTC clearance and confirm the final funding terms, closing costs, acquired earnings, and integration plan before adding exposure.
• Keep MDXG exposure cautious rather than making a high-conviction directional trade without valuation and post-call price data. Reassess after the final Medicare schedule and the next report; monitor Wound revenue/pricing and Surgical growth separately.
• Treat a Sanara close as a potential catalyst, not a standalone buy signal for SMTI: verify consideration, closing conditions, and the effect of the delay on its standalone outlook before positioning.
• Track whether Q4 EBITDA improvement is accompanied by sequential revenue growth and stable gross margin. A miss on either would challenge the cost-reset thesis; sustained Surgical growth plus Wound stabilization would strengthen it.